Diseases / Geographic Atrophy
Geographic Atrophy Clinical Trials
DiseaseGeographic atrophy is an advanced form of age-related macular degeneration characterized by progressive and irreversible retinal tissue loss leading to central vision decline. It is often referred to as atrophic AMD or advanced dry AMD. Disease progression substantially affects reading, face recognition, and other daily functions.
Continuously tracked·last revised
Data: CSV·JSON·Browse the trials
Follow Geographic Atrophy
Email me when this page changes — new trials, changes of phase or status, and results as they are posted.
No mail is going out yet — your address is recorded now, used for nothing else, and never shared.
Thanks — your request is recorded. No mail is sent yet.
That did not work. Check the address and try again.
Recruiting Phase 3
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| A Study Investigating Subcutaneously Administered Pozelimab in Combination With Cemdisiran or Cemdisiran Alone in Adult Participants With Geographic Atrophy NCT06541704 | Phase 3 | Recruiting | Regeneron Pharmaceuticals | Started 2024-10 |
| A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD) NCT06635148 | Phase 2/3 | Recruiting | Janssen Research & Development, LLC | Started 2024-09 |
| A Study in Adults With Geographic Atrophy NCT07606365 | Phase 2 | Recruiting | Sitala Bio LTD | Started 2026-09 |
| SGLT2 Inhibitors in Geographic Atrophy NCT07174687 | Phase 2 | Recruiting | Washington University School of Medicine | Started 2025-12 |
| Study to Evaluate Efficacy and Safety of ONL1204 in Patients With GA Associated With AMD NCT06659445 | Phase 2 | Recruiting | ONL Therapeutics | Started 2025-10 |
Recently started
| Trial | Phase | Status | Sponsor | Started |
|---|---|---|---|---|
| An Open-label Extension Study of the Long-Term Safety of Vonaprument (ANX007) in Participants With Dry Age-Related Macular Degeneration (AMD) With Geographic Atrophy (GA) NCT07807969 | Phase 3 | Not yet recruiting | Annexon, Inc. | Started 2026-09 |
| An Open-label Safety, Tolerability and Exploratory Efficacy Clinical Trial of PST-611 in Geographic Atrophy NCT07705568 | Phase 2 | Not yet recruiting | Eyevensys | Started 2026-09 |
| Adaptive Optics Scanning Light Ophthalmoscopy (AOSLO) and Microperimetry (MP) Sub-study NCT07747662 | Phase n/a | Enrolling by invitation | University of Wisconsin, Madison | Started 2026-09 |
| A Phase 1/2 Study of the Safety and Efficacy of BRX011 Oral Administration Once Daily in Subjects With Geographic Atrophy Secondary to Age-Related Macular Degeneration NCT07029945 | Phase 1/2 | Recruiting | Biojiva LLC | Started 2026-09 |
| A Study in Adults With Geographic Atrophy NCT07606365 | Phase 2 | Recruiting | Sitala Bio LTD | Started 2026-09 |
Results recently posted
| Trial | Phase | Status | Sponsor | Results posted |
|---|---|---|---|---|
| Retinal Fundus Flavoprotein Fluorescence in Age Related Macular Degeneration NCT06381596 | Phase n/a | Completed | University of Wisconsin, Madison | Results posted 2026-07-29 |
| COmparison of Clarus and Optos Ultrawide Field Imaging Systems for Geographic Atrophy NCT05961332 | Phase n/a | Completed | University of Wisconsin, Madison | Results posted 2026-06-15 |
| Avacincaptad Pegol Open-Label Extension for Patients With Geographic Atrophy NCT05536297 | Phase 3 | Completed | Astellas Pharma Global Development, Inc. | Results posted 2026-04-14 |
| Phase 2/3 Study of ALK-001 in Geographic Atrophy NCT03845582 | Phase 2/3 | Completed | Alkeus Pharmaceuticals, Inc. | Results posted 2025-10-16 |
| A Study of Danicopan in Participants With Geographic Atrophy Secondary to Age-Related Macular Degeneration NCT05019521 | Phase 2 | Terminated | Alexion Pharmaceuticals, Inc. | Results posted 2025-09-05 |
Pipeline
Phase by status
| Phase | Recruiting | Not yet | By invitation | Active | Completed | Terminated | Withdrawn | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|
| Early Phase 1 | — | 1 | — | — | — | — | — | — | 1 |
| Phase 1 | 3 | — | — | — | 14 | 1 | 1 | — | 19 |
| Phase 1/2 | 7 | — | — | 2 | 5 | 1 | — | 2 | 17 |
| Phase 2 | 6 | 1 | 1 | 3 | 18 | 12 | 3 | 1 | 45 |
| Phase 2/3 | 1 | — | — | — | 4 | — | — | — | 5 |
| Phase 3 | 1 | 1 | — | 2 | 8 | 4 | 1 | — | 17 |
| Phase 4 | — | — | — | 1 | 6 | — | — | — | 7 |
| Not applicable | 6 | 2 | 2 | 3 | 8 | 1 | 3 | 4 | 29 |
| Unknown | 7 | 2 | 1 | 4 | 15 | 5 | — | 3 | 37 |
Trials started per year
Conditions studied, by phase
| Condition | Early Phase 1 | Phase 1 | Phase 1/2 | Phase 2 | Phase 2/3 | Phase 3 | Phase 4 | Not applicable | Unknown | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Geographic Atrophy | 1 | 19 | 17 | 45 | 5 | 17 | 7 | 29 | 37 | 177 |
| Macular Degeneration | — | 9 | 10 | 29 | 3 | 9 | 7 | 23 | 25 | 115 |
| Retinal Diseases | — | 1 | 2 | 6 | — | 1 | 1 | 3 | 3 | 17 |
| Wet Macular Degeneration | — | 1 | — | 2 | — | 3 | 5 | 3 | 1 | 15 |
| Eye Diseases | — | 1 | 2 | 3 | — | 2 | 1 | 3 | 2 | 14 |
| Retinal Degeneration | — | 1 | 1 | 5 | — | 1 | 1 | 2 | 3 | 14 |
| Vision Disorders | — | — | 1 | 2 | — | 3 | 5 | 1 | — | 12 |
| Choroidal Neovascularization | — | 2 | — | — | — | 4 | 3 | — | 2 | 11 |
| Anetoderma | — | — | 1 | 3 | — | — | — | — | 2 | 6 |
| Retinal Vein Occlusion | — | 1 | — | 1 | — | 1 | 1 | — | 2 | 6 |
Most active sponsors
| # | Sponsor | Trials | Phase 3 |
|---|---|---|---|
| 1 | Novartis Pharmaceuticals | 14 | 3 |
| 2 | Genentech, Inc. | 8 | 0 |
| 3 | Apellis Pharmaceuticals, Inc. | 7 | 3 |
| 4 | Hoffmann-La Roche | 7 | 3 |
| 5 | Alcon Research | 5 | 1 |
| 6 | Gyroscope Therapeutics Limited | 5 | 0 |
| 7 | Janssen Research & Development, LLC | 5 | 1 |
| 8 | National Eye Institute (NEI) | 5 | 0 |
| 9 | Boehringer Ingelheim | 4 | 0 |
| 10 | Annexon, Inc. | 3 | 2 |
Most studied interventions
| # | Intervention | Trials |
|---|---|---|
| 1 | salicylhydroxamic acid | 13 |
| 2 | pegcetacoplan | 7 |
| 3 | Ranibizumab | 6 |
| 4 | brolucizumab | 5 |
| 5 | lampalizumab | 5 |
| 6 | emixustat | 3 |
| 7 | Sirolimus | 3 |
| 8 | aflibercept | 2 |
| 9 | Tacrolimus | 2 |
| 10 | Tomography, Optical Coherence | 2 |
Terminations
Stated reasons
Reasons are grouped from the sponsor's own wording with a rule-based classifier; the original text is shown below.
Recently stopped
| Trial | Status | Stated reason | Stopped |
|---|---|---|---|
| NCT06961370 Terminated | Terminated | The study was terminated prematurely by the Sponsor due to observation of dose-limiting adverse events meeting the protocol-defined stopping criteria. | 2026-03-03 |
| NCT05941273 Withdrawn | Withdrawn | This decision is driven by the sponsor's strategic considerations. | 2026-02-05 |
| NCT05019521 Terminated | Terminated | Lack of efficacy. | 2025-01-21 |
| NCT03846193 Terminated | Terminated | The study was terminated due to the interim analysis demonstrating lack of treatment efficacy. | 2024-06-25 |
| NCT04566445 Terminated | Terminated | Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns. | 2024-06-10 |
| NCT04437368 Terminated | Terminated | Terminated for interim analysis demonstrating futility (trial highly unlikely to meet efficacy outcome). The trial is not ending early because of medical problems or concerns. | 2024-04-05 |
| NCT03894020 Terminated | Terminated | The study was terminated due to the interim analysis demonstrating lack of treatment efficacy. | 2024-03-25 |
| NCT04607148 Terminated | Terminated | The benefit to risk balance did not support further treatment with galegenimab (FHTR2163). | 2022-11-14 |
| NCT03972709 Terminated | Terminated | The benefit to risk balance did not support further treatment with galegenimab (FHTR2163). | 2022-10-27 |
| NCT04643886 Terminated | Terminated | no further benefit | 2022-03-21 |
Evidence
- Results reported
- 64.1%50 of 78 completed
- Published
- 17.9%14 of 78 completed
- Primary endpoint met
- 27.8%20 of 72 analyses
- Median months to report
- 12
Documents disclosed
Trial profile
- Median enrollment
- 72
- Median duration
- 36.2months
- Countries
- 45
- Study sites
- 2765
Who is enrolled
Median enrollment by phase
- Early Phase 1
- 24
- Phase 1
- 24
- Phase 1/2
- 40
- Phase 2
- 143
- Phase 2/3
- 286
- Phase 3
- 621
- Phase 4
- 105
- Not applicable
- 38
- Unknown
- 150
Where trials run
Busiest cities
| # | City | Country | Trials |
|---|---|---|---|
| 1 | Dallas | United States | 49 |
| 2 | Austin | United States | 47 |
| 3 | Boston | United States | 43 |
| 4 | Beverly Hills | United States | 41 |
| 5 | Phoenix | United States | 40 |
| 6 | Philadelphia | United States | 38 |
| 7 | Reno | United States | 36 |
| 8 | The Woodlands | United States | 32 |
| 9 | Nashville | United States | 31 |
| 10 | Portland | United States | 31 |